Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme
The purpose of this study is to evaluate the safety, tolerability and efficacy of VB-111 in patients with Relapsed Glioblastoma Multiforme.
Glioblastoma Multiforme
DRUG: VB-111|DRUG: Bevacizumab
Overall Survival, From date of study entry until the date of death from any cause (up to 10 years)
Progression Free Survival, 6 months
The purpose of this study is to evaluate the safety, tolerability and efficacy of VB-111 in patients with Relapsed Glioblastoma Multiforme.